During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

A panelist discusses how prophylactic dermatologic management, including the proactive use of moisturizers, topical steroids, ...

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

Subcutaneous amivantamab is co-formulated Halozyme's ENHANZE ® drug delivery technology. "We are delighted to announce the European approval of the subcutaneous formulation of amivantamab ...

Johnson & Johnson (NYSE:JNJ) has announced that the U.S. FDA has declined to approve an injectable version of its cancer ...

Rybrevant (amivantamab) has been cleared in combination with chemotherapy for patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R mutations who have previously ...

Please provide your email address to receive an email when new articles are posted on . Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared ...

Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease ...

PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...

An enhanced prophylactic regimen using widely available and easy-to-use agents significantly reduced the incidence and severity of dermatologic reactions associated with first-line amivantamab ...

Cullinan Therapeutics (CGEM) announced that results from the REZILIENT1 study of zipalertinib in non-small cell lung cancer patients with EGFR ...